TR201902314T4 - Azol benzen türevi ve bunun kristali. - Google Patents

Azol benzen türevi ve bunun kristali. Download PDF

Info

Publication number
TR201902314T4
TR201902314T4 TR2019/02314T TR201902314T TR201902314T4 TR 201902314 T4 TR201902314 T4 TR 201902314T4 TR 2019/02314 T TR2019/02314 T TR 2019/02314T TR 201902314 T TR201902314 T TR 201902314T TR 201902314 T4 TR201902314 T4 TR 201902314T4
Authority
TR
Turkey
Prior art keywords
crystal
benzene derivative
azole benzene
azole
hyperuricemia
Prior art date
Application number
TR2019/02314T
Other languages
English (en)
Inventor
Kawana Asahi
Nozato Hisae
Kanazawa Chikashi
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of TR201902314T4 publication Critical patent/TR201902314T4/tr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/04Drugs for disorders of the urinary system for urolithiasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Şunlar sağlanır: Gut, hiperürisemi ve benzeri için bir terapötik ajan ve bir profilaktik ajan olarak kullanışlı olan 4-metil-2-[4-(2-metilpropoksi)-3-(1H-1,2,3,4-tetrazol-1-il)fenil]-1,3-tiyazol-5-karboksilik asit, bunun bir sodyum tuzu ve bunların kristalleri.
TR2019/02314T 2014-07-30 2015-07-29 Azol benzen türevi ve bunun kristali. TR201902314T4 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014155032 2014-07-30
JP2014155030 2014-07-30

Publications (1)

Publication Number Publication Date
TR201902314T4 true TR201902314T4 (tr) 2019-03-21

Family

ID=55217605

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/02314T TR201902314T4 (tr) 2014-07-30 2015-07-29 Azol benzen türevi ve bunun kristali.

Country Status (31)

Country Link
US (1) US10179780B2 (tr)
EP (1) EP3176166B1 (tr)
JP (1) JP6279085B2 (tr)
KR (1) KR102474325B1 (tr)
CN (1) CN106661014B (tr)
AU (1) AU2015297501B2 (tr)
BR (1) BR112017001657B1 (tr)
CA (1) CA2956553C (tr)
CY (1) CY1121189T1 (tr)
DK (1) DK3176166T3 (tr)
ES (1) ES2712850T3 (tr)
HR (1) HRP20182084T1 (tr)
HU (1) HUE042576T2 (tr)
IL (1) IL250143B (tr)
LT (1) LT3176166T (tr)
ME (1) ME03319B (tr)
MX (1) MX370524B (tr)
MY (1) MY180730A (tr)
NZ (1) NZ729068A (tr)
PH (1) PH12017500124B1 (tr)
PL (1) PL3176166T3 (tr)
PT (1) PT3176166T (tr)
RS (1) RS58315B1 (tr)
RU (1) RU2701515C2 (tr)
SA (1) SA517380787B1 (tr)
SG (1) SG11201700741WA (tr)
SI (1) SI3176166T1 (tr)
TR (1) TR201902314T4 (tr)
TW (1) TWI688563B (tr)
WO (1) WO2016017708A1 (tr)
ZA (1) ZA201700664B (tr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2955577A1 (en) * 2014-07-30 2016-02-04 Teijin Pharma Limited Xanthine oxidase inhibitor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992009279A1 (en) 1990-11-30 1992-06-11 Teijin Limited 2-arylthiazole derivative and pharmaceutical composition containing the same
AU703609B2 (en) 1995-04-07 1999-03-25 Teijin Limited Protective agent for organ or tissue
AU748026B2 (en) 1998-06-19 2002-05-30 Teijin Limited Polymorphic modifications of 2-(3-cyano-4-isobutyloxyphenyl)- 4-methyl-5-thiazole-carboxylic acid and processes for the preparation thereof
JP2002105067A (ja) 2000-09-28 2002-04-10 Teijin Ltd 2−フェニルチアゾール誘導体、およびそれを有効成分とする医薬組成物
EP1932833B1 (en) 2005-10-07 2012-08-01 Kissei Pharmaceutical Co., Ltd. Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
WO2008126770A1 (ja) 2007-04-05 2008-10-23 Astellas Pharma Inc. トリアリールカルボン酸誘導体の製造方法
CA2682393C (en) 2007-04-11 2015-03-17 Kissei Pharmaceutical Co., Ltd. 5-membered heterocyclic derivative and use thereof for medical purposes
WO2010018458A2 (en) 2008-08-12 2010-02-18 Crystalgenomics, Inc. Phenol derivatives and methods of use thereof
WO2010128163A2 (en) 2009-05-08 2010-11-11 Pike Pharma Gmbh Small molecule inhibitors of influenza a and b virus and respiratory syncytial virus replication
WO2011101867A2 (en) 2010-02-19 2011-08-25 Cadila Healthcare Limited Substantially pure salts of febuxostat and processes for preparation thereof
WO2011139886A2 (en) 2010-04-29 2011-11-10 Dr. Reddy's Laboratories Ltd. Preparation of febuxostat
TWI606048B (zh) 2013-01-31 2017-11-21 帝人製藥股份有限公司 唑苯衍生物

Also Published As

Publication number Publication date
PL3176166T3 (pl) 2019-06-28
MX2017000412A (es) 2017-04-27
EP3176166A4 (en) 2017-06-21
PT3176166T (pt) 2019-02-04
HRP20182084T1 (hr) 2019-02-08
CY1121189T1 (el) 2020-05-29
RU2017106052A (ru) 2018-08-28
PH12017500124A1 (en) 2017-05-29
HUE042576T2 (hu) 2019-07-29
US10179780B2 (en) 2019-01-15
CA2956553A1 (en) 2016-02-04
TW201617341A (zh) 2016-05-16
IL250143B (en) 2019-11-28
ME03319B (me) 2019-10-20
PH12017500124B1 (en) 2017-05-29
ES2712850T3 (es) 2019-05-16
AU2015297501A1 (en) 2017-03-09
MX370524B (es) 2019-12-17
MY180730A (en) 2020-12-08
BR112017001657B1 (pt) 2023-01-17
CA2956553C (en) 2023-03-21
BR112017001657A2 (pt) 2018-01-30
IL250143A0 (en) 2017-03-30
EP3176166B1 (en) 2018-11-28
JP6279085B2 (ja) 2018-02-14
WO2016017708A1 (ja) 2016-02-04
KR102474325B1 (ko) 2022-12-05
ZA201700664B (en) 2019-06-26
NZ729068A (en) 2022-05-27
TWI688563B (zh) 2020-03-21
RU2701515C2 (ru) 2019-09-27
SG11201700741WA (en) 2017-02-27
CN106661014B (zh) 2019-12-24
AU2015297501B2 (en) 2019-07-04
EP3176166A1 (en) 2017-06-07
CN106661014A (zh) 2017-05-10
KR20170033320A (ko) 2017-03-24
JPWO2016017708A1 (ja) 2017-04-27
RS58315B1 (sr) 2019-03-29
SI3176166T1 (sl) 2019-01-31
SA517380787B1 (ar) 2021-03-11
US20170247364A1 (en) 2017-08-31
RU2017106052A3 (tr) 2018-08-28
DK3176166T3 (en) 2019-02-18
LT3176166T (lt) 2019-01-10

Similar Documents

Publication Publication Date Title
CU20170057A7 (es) Derivados de feniltriazol sustituido con hidroxialquilo
AR116394A2 (es) Mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato
MD3442580T2 (ro) Metode de tratament pentru bolile colestatice și fibrotice
MA49879A (fr) Composés hétérocycliques utiles en tant qu'inhibiteurs doubles d'atx/ca
HUE046008T2 (hu) I-(5-terc-butil)-izoxazol-3-il)-3-(4-((feniI)-etinil)-fenil)-kabamid származékok, valamint az ezekkel rokon vegyületek FLT-3 inhibitorokként rák kezelésére
UY35998A (es) 1-(3-(tert-BUTIL)1-(p-TOLIL)-1H-PIRAZOL-5-IL)-3-(4-((2-((6-ETILPIRAZIN-2-IL)AMINO)PIRIDIN-4-IL)METOXI)NAFTALEN-1-IL) UREA Y SUS SALES DERIVADAS FARMACÉUTICAMENTE ACEPTABLES, COMO INHIBIDORES DE P38 M AP QUINASA
BR112017006420A2 (pt) derivados de ácido borônico
UY37517A (es) Métodos de síntesis de compuestos tiazoles sustituidos
RS60764B1 (sr) Derivati 5-[2-(piridin-2-ilamino)-1,3-tiazol-5-il]-2,3-dihidro-1h-izoindol-1-ona i njihova upotreba kao dvojnih inhibitora fosfatidilinozitol 3-kinaze delta i gama
MY195889A (en) Phenyl Derivatives as Cannabinoid Receptor 2 Agonists
CL2018001408A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer
PH12017500123B1 (en) Crystal of azole benzene derivative
TR201902314T4 (tr) Azol benzen türevi ve bunun kristali.
EP3749647C0 (en) N-(5-(PHENYL)-1H-PYRAZOL-3-YL)-1H-INDOL-5-AMINE DERIVATIVES AS TNIK INHIBITORS FOR THE TREATMENT OF CANCER
CL2012002452A1 (es) Procedimientos para la preparacion de 2-(ciclohexilmetil)-n-{2-[(2s)-1-metilpirrolidin-2-il] etil}-1,2,3,4-tetrahidroisoquinolin-7-sulfonamida; uno de sus compuestos interemdiarios; y la preparacion del mismo.
DK3790873T3 (da) 1h-indazol-3-carboxamidforbindelser som glycogensynthase-kinase-3-beta-inhibitorer
NZ716494A (en) Processes and intermediates for the preparation of a pde10 inhibitor
CO2018000953A2 (es) Asociación entre la 3 - [(3 - {[4- (4-morfolinilmetil) -1h-pirrol-2-il] metilen} -2-oxo-2,3-dihidro-1h-indol-5-il) metil ] -1,3-tiazolidina-2,4-diona y un inhibidor de la tyr quinasa del egfr
AR101362A1 (es) Derivado de azol benceno y forma cristalina del mismo
ES2723429T3 (es) Formulación de nanopartículas que comprende un inhibidor de mPGES-1
UA114081U (uk) 5-(2-(4-(диметиламіно)бензиліден)гідразиніл)-4-феніл-4h-1,2,4-триазол-3-тіолу гідрохлорид, що стимулює ріст пшениці озимої
TH168005B (th) สารอนุพันธ์เอโซล เบนซีน และรูปผลึกของสารนั้น
UA98919U (ru) 4-этил-3-(феноксиметил)-5-((2-((5-феноксиметил)-4-фенил-4н-1,2,4-триазол-3-ил)тио)этил)тио)-4н-1,2,4-триазол, проявляющая диуретическую активность
UA97633U (xx) 3-((2-хлоретил)тіо)-5-(4-метоксифеніл)-1н-1,2,4-триазол, що проявляє гіпоглікемічну активність
TH168006B (th) สารอนุพันธ์เอโซล เบนซีน และรูปผลึกของสารนั้น